North Fourth Asset Management LP Takes Position in CVS Health (CVS)

North Fourth Asset Management LP purchased a new stake in shares of CVS Health (NYSE:CVS) during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 20,000 shares of the pharmacy operator’s stock, valued at approximately $1,450,000.

Other hedge funds have also recently bought and sold shares of the company. Wealthcare Advisory Partners LLC lifted its holdings in CVS Health by 330.3% in the third quarter. Wealthcare Advisory Partners LLC now owns 1,291 shares of the pharmacy operator’s stock valued at $105,000 after acquiring an additional 991 shares during the period. Fieldpoint Private Securities LLC lifted its holdings in CVS Health by 333.3% in the second quarter. Fieldpoint Private Securities LLC now owns 1,300 shares of the pharmacy operator’s stock valued at $105,000 after acquiring an additional 1,000 shares during the period. Cerebellum GP LLC bought a new position in CVS Health in the fourth quarter valued at about $130,000. Capital Analysts LLC lifted its holdings in CVS Health by 240.1% in the fourth quarter. Capital Analysts LLC now owns 3,177 shares of the pharmacy operator’s stock valued at $137,000 after acquiring an additional 2,243 shares during the period. Finally, Valeo Financial Advisors LLC bought a new position in CVS Health in the third quarter valued at about $159,000. 84.01% of the stock is currently owned by institutional investors.

How to Become a New Pot Stock Millionaire

NYSE:CVS opened at $66.60 on Wednesday. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.02 and a quick ratio of 0.52. CVS Health has a 12-month low of $60.14 and a 12-month high of $84.00. The stock has a market cap of $66,066.33, a P/E ratio of 11.29, a price-to-earnings-growth ratio of 1.11 and a beta of 1.05.



CVS Health (NYSE:CVS) last released its earnings results on Thursday, February 8th. The pharmacy operator reported $1.92 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.88 by $0.04. CVS Health had a return on equity of 17.21% and a net margin of 3.58%. The firm had revenue of $48.39 billion during the quarter, compared to analysts’ expectations of $47.54 billion. During the same quarter last year, the business posted $1.71 earnings per share. The firm’s revenue was up 5.3% on a year-over-year basis. research analysts anticipate that CVS Health will post 6.32 EPS for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Thursday, May 3rd. Investors of record on Monday, April 23rd will be given a dividend of $0.50 per share. This represents a $2.00 annualized dividend and a dividend yield of 3.00%. The ex-dividend date of this dividend is Friday, April 20th. CVS Health’s dividend payout ratio is currently 33.90%.

In related news, EVP Helena Foulkes sold 19,965 shares of the stock in a transaction dated Friday, February 16th. The stock was sold at an average price of $71.04, for a total transaction of $1,418,313.60. Following the completion of the sale, the executive vice president now owns 65,072 shares in the company, valued at $4,622,714.88. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 0.61% of the company’s stock.

A number of research analysts have weighed in on the company. Morgan Stanley raised CVS Health from an “equal weight” rating to an “overweight” rating and set a $88.00 target price on the stock in a report on Friday, January 5th. Needham & Company LLC increased their target price on CVS Health from $85.00 to $88.00 and gave the company a “buy” rating in a report on Tuesday, January 2nd. SunTrust Banks increased their target price on CVS Health to $90.00 and gave the company a “buy” rating in a report on Friday, January 5th. Leerink Swann set a $85.00 target price on CVS Health and gave the company a “buy” rating in a report on Friday, February 9th. Finally, Mizuho set a $95.00 target price on CVS Health and gave the company a “buy” rating in a report on Wednesday, January 24th. Two equities research analysts have rated the stock with a sell rating, seven have issued a hold rating, twelve have issued a buy rating and two have issued a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus target price of $86.65.

TRADEMARK VIOLATION NOTICE: “North Fourth Asset Management LP Takes Position in CVS Health (CVS)” was first reported by StockNewsTimes and is the property of of StockNewsTimes. If you are viewing this report on another website, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark law. The legal version of this report can be accessed at https://stocknewstimes.com/2018/04/25/north-fourth-asset-management-lp-takes-position-in-cvs-health-cvs.html.

CVS Health Profile

CVS Health Corporation, together with its subsidiaries, provides integrated pharmacy health care services. It operates through Pharmacy Services and Retail/LTC segments. The Pharmacy Services segment offers pharmacy benefit management solutions, such as plan design and administration, formulary management, Medicare Part D services, mail order, specialty pharmacy and infusion services, retail pharmacy network management services, prescription management systems, clinical services, disease management programs, and medical pharmacy management services.

Want to see what other hedge funds are holding CVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CVS Health (NYSE:CVS).

Institutional Ownership by Quarter for CVS Health (NYSE:CVS)

Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply